Cargando…
The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
INTRODUCTION: Cardiotoxicity is a well known long-term consequence of lung cancer chemotherapy, however little is known about early subclinical changes in cardiac function. AIM: The goal of the study was to assess early cardiotoxic effects of cisplatin-containing chemotherapy in stage III and IV lun...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Communications and Publications Division (CPD) of the IFCC
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975326/ https://www.ncbi.nlm.nih.gov/pubmed/27683384 |
_version_ | 1782446706204344320 |
---|---|
author | Demkow, Urszula Biatas-Chromiec, Beata Stelmaszczyk-Emmel, Anna Radzikowska, Elzbieta Wiatr, Elzbieta Radwan-Rohrenschef, Piotr Szturmowicz, Monika |
author_facet | Demkow, Urszula Biatas-Chromiec, Beata Stelmaszczyk-Emmel, Anna Radzikowska, Elzbieta Wiatr, Elzbieta Radwan-Rohrenschef, Piotr Szturmowicz, Monika |
author_sort | Demkow, Urszula |
collection | PubMed |
description | INTRODUCTION: Cardiotoxicity is a well known long-term consequence of lung cancer chemotherapy, however little is known about early subclinical changes in cardiac function. AIM: The goal of the study was to assess early cardiotoxic effects of cisplatin-containing chemotherapy in stage III and IV lung cancer patients, measuring serum levels of selected cardiac markers in relation to oxidant effects. METHODS: We quantified the immediate impact of chemotherapy on cardiac troponin T (TnT), creatine kinase-myocardial band (CK-MB) and N- terminal pro-brain natriuretic peptide (NT-proBNP) in blood samples obtained from 12 non-small cell lung cancer (NSCLC) patients. All markers were measured using commercially available immunoassays. To investigate the oxidant effects of cisplatin-containing chemotherapy, we evaluated reduced glutathione (GSH), nitrite (NO2), derivatives of reactive oxygen metabolites (d-ROMs) and thiols (SH). Samples were collected prior to chemotherapy and 1 day after the first cycle of cisplatin administration. RESULTS: Chemotherapy did not cause statistically significant elevations in serum CK-MB. Serum TnT levels were undetectable at both time points in 11 out of 12 patients with a threshold of 0.01 ng/ml. In the single patient with undetectable TnT at the baseline, after the first infusion TnT level reversibly rose to 0.03 ng/ml. The pre-treatment value of NT-proBNP was slightly elevated in 7 out of 12 lung cancer patients. In 1 case NT-proBNP level significantly increased after chemotherapy (from 221.8 to 1489.0 pg/ml p<0.001), in the remaining 11 patients it was stable Cisplatin-based combination chemotherapy induced significant nitrite production in 5 patients (p<0.05). The other measured oxidative stress parameters remained unchanged after the first infusion. CONCLUSION: This pilot study demonstrated occasional elevations of cardiac biomarkers during cisplatin administration. Administration of cisplatin-containing chemotherapy caused significant nitroxidative stress in some patients. The relevance of cardiovascular complications in cancer patients and identification individual risk factors of developing cardiovascular toxicity merit further evaluation. |
format | Online Article Text |
id | pubmed-4975326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | The Communications and Publications Division (CPD) of the IFCC |
record_format | MEDLINE/PubMed |
spelling | pubmed-49753262016-09-28 The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy Demkow, Urszula Biatas-Chromiec, Beata Stelmaszczyk-Emmel, Anna Radzikowska, Elzbieta Wiatr, Elzbieta Radwan-Rohrenschef, Piotr Szturmowicz, Monika EJIFCC Research Article INTRODUCTION: Cardiotoxicity is a well known long-term consequence of lung cancer chemotherapy, however little is known about early subclinical changes in cardiac function. AIM: The goal of the study was to assess early cardiotoxic effects of cisplatin-containing chemotherapy in stage III and IV lung cancer patients, measuring serum levels of selected cardiac markers in relation to oxidant effects. METHODS: We quantified the immediate impact of chemotherapy on cardiac troponin T (TnT), creatine kinase-myocardial band (CK-MB) and N- terminal pro-brain natriuretic peptide (NT-proBNP) in blood samples obtained from 12 non-small cell lung cancer (NSCLC) patients. All markers were measured using commercially available immunoassays. To investigate the oxidant effects of cisplatin-containing chemotherapy, we evaluated reduced glutathione (GSH), nitrite (NO2), derivatives of reactive oxygen metabolites (d-ROMs) and thiols (SH). Samples were collected prior to chemotherapy and 1 day after the first cycle of cisplatin administration. RESULTS: Chemotherapy did not cause statistically significant elevations in serum CK-MB. Serum TnT levels were undetectable at both time points in 11 out of 12 patients with a threshold of 0.01 ng/ml. In the single patient with undetectable TnT at the baseline, after the first infusion TnT level reversibly rose to 0.03 ng/ml. The pre-treatment value of NT-proBNP was slightly elevated in 7 out of 12 lung cancer patients. In 1 case NT-proBNP level significantly increased after chemotherapy (from 221.8 to 1489.0 pg/ml p<0.001), in the remaining 11 patients it was stable Cisplatin-based combination chemotherapy induced significant nitrite production in 5 patients (p<0.05). The other measured oxidative stress parameters remained unchanged after the first infusion. CONCLUSION: This pilot study demonstrated occasional elevations of cardiac biomarkers during cisplatin administration. Administration of cisplatin-containing chemotherapy caused significant nitroxidative stress in some patients. The relevance of cardiovascular complications in cancer patients and identification individual risk factors of developing cardiovascular toxicity merit further evaluation. The Communications and Publications Division (CPD) of the IFCC 2011-03-14 /pmc/articles/PMC4975326/ /pubmed/27683384 Text en Copyright © 2011 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Demkow, Urszula Biatas-Chromiec, Beata Stelmaszczyk-Emmel, Anna Radzikowska, Elzbieta Wiatr, Elzbieta Radwan-Rohrenschef, Piotr Szturmowicz, Monika The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy |
title | The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy |
title_full | The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy |
title_fullStr | The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy |
title_full_unstemmed | The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy |
title_short | The Cardiac Markers and Oxidative Stress Parameters in Advanced Non-Small Cell Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy |
title_sort | cardiac markers and oxidative stress parameters in advanced non-small cell lung cancer patients receiving cisplatin-based chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975326/ https://www.ncbi.nlm.nih.gov/pubmed/27683384 |
work_keys_str_mv | AT demkowurszula thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT biataschromiecbeata thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT stelmaszczykemmelanna thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT radzikowskaelzbieta thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT wiatrelzbieta thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT radwanrohrenschefpiotr thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT szturmowiczmonika thecardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT demkowurszula cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT biataschromiecbeata cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT stelmaszczykemmelanna cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT radzikowskaelzbieta cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT wiatrelzbieta cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT radwanrohrenschefpiotr cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy AT szturmowiczmonika cardiacmarkersandoxidativestressparametersinadvancednonsmallcelllungcancerpatientsreceivingcisplatinbasedchemotherapy |